3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
150
Stomach Neoplasms
52
Neoplasms
49
Pancreatic Neoplasms
41
Neoplasm Metastasis
32
Squamous Cell Carcinoma of Head and Neck
26
Head and Neck Neoplasms
25
Esophageal Neoplasms
24
Colonic Neoplasms
22
Rectal Neoplasms
21
Carcinoma, Non-Small-Cell Lung
21
Breast Neoplasms
20
Parkinson Disease 4, Autosomal Dominant Lewy Body
19
Esophageal Squamous Cell Carcinoma
15
Adenocarcinoma
14
Adenocarcinoma Of Esophagus
12
Cholangiocarcinoma
11
Biliary Tract Neoplasms
11
Ovarian Neoplasms
9
Triple Negative Breast Neoplasms
7
Gallbladder Neoplasms
7
Carcinoma, Hepatocellular
7
Carcinoma
7
Urinary Bladder Neoplasms
6
Sarcoma
6
Keratosis, Actinic
6
Gastrointestinal Neoplasms
6
Endometrial Neoplasms
6
Carcinoma, Squamous Cell
6
Advanced Solid Tumors
6
Interventions
lutetium Lu 177 dotatate
3
Octreotide
3
pasireotide
2
lanreotide
2
amino-acid, glucose, and electrolyte solution
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
famitinib
1
copper dotatate CU-64
1
arginyllysine
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
PM 01183
1
Oxaliplatin
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastro-enteropancreatic neuroendocrine tumor
×
Fluorouracil
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled